Table 2.

Genotype and allele frequencies of thrombotic gene variants in the study population

SNP	Genotypes	Controls (n = 34)	Patients (n = 23)	P values	Crude OR (95% CI)	Adjusted OR (95% CI)
FV: Leiden	Normal	32 (94.1)	20 (87.0)	0.384	1.0	1.0
1691G > A	Hetero	2 (5.9)	3 (13.0)		2.4 (0.3–15.6)	3.08 (0.3–26.3)
	p HWE	0.859	0.737
	MAF (A)	0.03	0.07	0.359	0.4 (0.05–3.1)
FV: R2	Normal	30 (8 8.2)	14 (60.9)	0.024	1.0	1.0
H1299R	Hetero	4 (11.8)	9 (39.1)		4.8 (1.2–18.3)	7.1 (1.49–33.6)
4070A > G	p HWE	0.715	0.243
	MAF (G)	0.06	0.20	0.024	3.8 (1.12–13.5)
FII: PTH	Normal	34 (100)	23 (100)	NA	NA
20210G > A	p HWE	NA	NA
FXIII	Normal	30 (88.2)	17 (73.9)	0.287	1.0	1.0
V34L	Hetero	4 (11.8)	6 (26.1)		2.6 (0.6–10.7)	2.29 (0.48–1.5)
	p HWE	0.715	0.471
	MAF (T)	0.06	0.13	0.185	0.4 (0.09–1.6)
MTHFR	Normal	22 (64.7)	12 (52.2)	0.017	1.0	1.0
677C > T	Hetero	12 (35.3)	6 (26.1)		0.9 (0.2–3.1)	0.82 (0.21–3.3)
	Homo	0 (0.0)	5 (21.7)		19 (1.0–388)
	Dominant model	12 (35.3)	11 (47.8)		1.6 (0.5–4.9)
	p HWE	0.211	0.041
	MAF (T)	0.18	0.35	0.037	2.4 (1.04–5.9)
MTHFR	Normal	10 (29.4)	8 (34.8)	0.648	1.0	1.0
1298A > C	Hetero	16 (47.1)	8 (34.8)		0.6 (0.1–2.2)	0.87 (0.21–3.6)
	Homo	8 (23.5)	7 (30.4)		1.1 (0.2–4.3)	1.46 (0.33–6.4)
	Dominant model	24 (70.6)	15 (65.2)		0.7 (0.2–2.4)
	p HWE	0.745	0.146
	MAF (C)	0.47	0.48	0.935	0.9 (0.4–2.1)
PAI-1	4G/4G	10 (29.4)	7 (30.4)	0.698	1.0	1.0
4G/5G	4G/5G	18 (52.9)	10 (43.5)		0.7 (0.2–2.7)	1.15 (0.24–5.3)
	5G/5G	6 (17.6)	6 (26.1)		1.4 (0.3–6.3)	1.36 (0.27–6.8)
	Dominant model	24 (70.5)	16 (69.6)		0.9 (0.3–3.0)
	p HWE	0.667	0.536
	MAF (5G)	0.44	0.48	0.696	0.8 (0.4–1.8)

FV coagulation factor 5, PTH Prothrombin, FXIII coagulation factor 13, MTHFR Methylenetetrahydrofolate reductase, PAI-1 plasminogen activator inhibitor-1

Fisher’s Exact and Chi-square tests were used; adjusted by potential confounders (gender, age, BMI, FH, DM, obesity). Bold values indicate statistically significant at p < 0.05